Liaison XL分析仪自动化QuantiFERON-TB Gold Plus检测中γ干扰素反应偏高:低发病率环境下减少假阳性的检测策略
本研究评估了Liaison XL化学发光免疫分析仪(CLIA)自动化检测QuantiFERON-TB Gold Plus(QFT-Plus)中γ干扰素(IFN-γ)的准确性。278例患者血浆样本先用酶联免疫吸附试验(ELISA)检测,再用CLIA检测;在220例ELISA临界阴性样本中研究了三种减少CLIA假阳性的策略。结果显示CLIA测量值普遍高于ELISA,假阳性风险增加,建议用ELISA确认临界阳性结果。
要点
- CLIA与ELISA的阳性符合率为91.7%,阴性符合率为95.2%。
- 在ELISA临界阴性样本中,CLIA阳性率为42.7%。
- 用ELISA复检CLIA假阳性可将假阳性率降低84.3%。
核心结论
- 在低发病率环境中使用Liaison CLIA进行QFT-Plus检测可能导致假阳性率升高,增加过度治疗风险。
研究设计与样本
- 研究纳入278例接受QFT-Plus检测的患者血浆样本,先用ELISA检测(150例阴性、128例阳性),再用CLIA检测。
- 在220例ELISA临界阴性样本中评估了三种减少CLIA假阳性的策略。
主要发现
- Bland-Altman分析显示CLIA测量的IFN-γ值高于ELISA,偏倚为0.21 IU/mL(标准差0.61;95% CI -1.0至1.41)。
- CLIA与ELISA的阳性符合率为91.7%(121/132),阴性符合率为95.2%(139/146)。
- 在ELISA临界阴性样本中,CLIA阳性率为42.7%(94/220),采用标准曲线后阳性率为36.4%(80/220)。
- 用ELISA复检CLIA假阳性(TB1或TB2范围0至≤1.3 IU/mL)可将假阳性率降低84.3%(59/70),而用CLIA复检仅降低10.4%(8/77)。
临床怎么用
- 在低发病率环境中使用Liaison CLIA进行QFT-Plus检测时,建议对临界阳性结果用ELISA确认以减少假阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Liaison XL chemiluminescence immunoassay (CLIA) analyzer allows total automation of gamma interferon (IFN-γ) measurement for the QuantiFERON-TB Gold Plus assay (QFT-Plus) that is used to diagnose Mycobacterium tuberculosis infection. To evaluate CLIA accuracy, plasma samples from 278 patients undergoing QFT-Plus testing were first tested with an enzyme-linked immunosorbent assay (ELISA; 150 negatives and 128 positives) and subsequently with the CLIA. Three strategies to mitigate false-positive CLIA results were investigated in 220 samples with borderline-negative ELISA results (TB1 and/or TB2, 0.1 to 0.34 IU/mL). The Bland-Altman plot of difference versus average of the two IFN-γ measurements in the Nil and antigen (TB1 and TB2) tubes showed higher IFN-γ measurements across the range of values with the CLIA than with the ELISA. Bias was 0.21 IU/mL (standard deviation, 0.61; 95% confidence interval [CI], -1.0 to 1.41). Linear regression of difference versus average had a slope of 0.08 (95% CI, 0.05 to 0.10), which was significantly nonzero (P < 0.0001). The CLIA had positive and negative percent agreement levels with the ELISA of 91.7% (121/132) and 95.2% (139/146), respectively. In borderline-negative samples tested with ELISA, CLIA was positive in 42.7% (94/220). CLIA with a standard curve resulted in 36.4% (80/220) positivity. Retesting CLIA false positives (TB1 or TB2 range, 0 to ≤1.3 IU/mL) with ELISA reduced false positives by 84.3% (59/70). Retesting with CLIA reduced the false-positive rate by 10.4% (8/77). Implementing the Liaison CLIA for QFT-Plus in low-incidence settings risks falsely elevating conversion rates and overburdening clinics and overtreating patients. Confirming borderline positives with ELISA is a viable strategy to mitigate false-positive CLIA results.
引用
- Buron V, Banaei N. Inflated Gamma Interferon Response with QuantiFERON-TB Gold Plus Using the Automated Liaison XL Analyzer: a Testing Algorithm To Mitigate False-Positive Results in Low-Incidence Settings. J Clin Microbiol. 2023. PMID: 37195172. doi:10.1128/jcm.00295-23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。